The PARC study: A phase I/II study evaluating the safety and activity of Pegylated recombinant human Arginase (BCT-100) Relapsed/refractory Cancers of Children and Young Adults
- Kirby, Maria L (Primary Chief Investigator (PCI))
- McCowage, Geoff (Chief Investigator (CI))
- Ziegler, David (Chief Investigator (CI))
- Mussai, Francis (Chief Investigator (CI))
- Strong, Robyn, (Chief Investigator (CI))
- Jones, Janelle, (Associate Investigator (AI))
Project: Research